ASLN - ASLAN Pharmaceuticals Ltd

0.6
-0.100   -16.650%

Share volume: 806,352
Last Updated: 07-18-2024

PREVIOUS CLOSE
CHG
CHG%
$0.70
-0.10
-14.27%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.60
P/E Ratio 
0.00
DAY RANGE
$0.60 - $0.70
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
2.828 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Carl Aslan Jason Morton Firth
Region: US
Website: www.aslanpharma.com
Employees: 30
IPO year: 2018
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry:
Sector:

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications. ASLAN003 is a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.

Recent news